These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 38621403)

  • 1. Study bolsters concerns about US FDA accelerated drug approvals.
    Furlow B
    Lancet Oncol; 2024 May; 25(5):543. PubMed ID: 38621403
    [No Abstract]   [Full Text] [Related]  

  • 2. A fresh perspective on comparing the FDA and the CHMP/EMA: approval of antineoplastic tyrosine kinase inhibitors.
    Shah RR; Roberts SA; Shah DR
    Br J Clin Pharmacol; 2013 Sep; 76(3):396-411. PubMed ID: 23362829
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Approvals in 2021: dangling Accelerated Approvals, drug dosing, new approvals and beyond.
    Lemery S; Pazdur R
    Nat Rev Clin Oncol; 2022 Apr; 19(4):217-218. PubMed ID: 35136230
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of FDA accelerated vs regular pathway approvals for lung cancer treatments between 2006 and 2018.
    Ribeiro TB; Buss L; Wayant C; Nobre MRC
    PLoS One; 2020; 15(7):e0236345. PubMed ID: 32706800
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of multiple endpoints and approval paths depicts a decade of FDA oncology drug approvals.
    Shea MB; Roberts SA; Walrath JC; Allen JD; Sigal EV
    Clin Cancer Res; 2013 Jul; 19(14):3722-31. PubMed ID: 23665737
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of Control Arm Quality in Randomized Clinical Trials Leading to Anticancer Drug Approval by the US Food and Drug Administration.
    Hilal T; Sonbol MB; Prasad V
    JAMA Oncol; 2019 Jun; 5(6):887-892. PubMed ID: 31046071
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FDA new drug approvals in Q1 2021.
    Urquhart L
    Nat Rev Drug Discov; 2021 May; 20(5):334. PubMed ID: 33854219
    [No Abstract]   [Full Text] [Related]  

  • 8. Single-arm clinical trials that supported FDA accelerated approvals have modest effect sizes and were at high risk of bias.
    Ribeiro TB; Colunga-Lozano LE; Araujo APV; Bennett CL; Hozo I; Djulbegovic B
    J Clin Epidemiol; 2022 Aug; 148():193-195. PubMed ID: 35093531
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Single-arm trials for US Food and Drug Administration cancer drug approvals: Although there are some challenges in using single-arm studies for accelerated drug approvals, it can make a difference in getting drugs previously approved for other uses to patients.: Although there are some challenges in using single-arm studies for accelerated drug approvals, it can make a difference in getting drugs previously approved for other uses to patients.
    Nierengarten MB
    Cancer; 2023 Jun; 129(11):1626. PubMed ID: 37158643
    [No Abstract]   [Full Text] [Related]  

  • 10. Exposure to US Cancer Drugs With Lack of Confirmed Benefit After US Food and Drug Administration Accelerated Approval.
    Parikh RB; Hubbard RA; Wang E; Royce TJ; Cohen AB; Clark AS; Mamtani R
    JAMA Oncol; 2023 Apr; 9(4):567-569. PubMed ID: 36821118
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 2011 FDA drug approvals.
    Mullard A
    Nat Rev Drug Discov; 2012 Feb; 11(2):91-4. PubMed ID: 22293555
    [No Abstract]   [Full Text] [Related]  

  • 12. New Indications and Approvals for Anticancer Drugs.
    Aschenbrenner DS
    Am J Nurs; 2021 Dec; 121(12):16-17. PubMed ID: 34792500
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An empirical analysis of overall survival in drug approvals by the US FDA (2006-2023).
    Elbaz J; Haslam A; Prasad V
    Cancer Med; 2024 Apr; 13(8):e7190. PubMed ID: 38659418
    [TBL] [Abstract][Full Text] [Related]  

  • 14. U.S. Food and Drug Administration anticancer drug approval trends from 2016 to 2018 for lung, colorectal, breast, and prostate cancer.
    Ribeiro TB; Ribeiro A; Rodrigues LO; Harada G; Nobre MRC
    Int J Technol Assess Health Care; 2020; 36(1):20-28. PubMed ID: 31775939
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Accelerated approval of cancer drugs: improved access to therapeutic breakthroughs or early release of unsafe and ineffective drugs?
    Richey EA; Lyons EA; Nebeker JR; Shankaran V; McKoy JM; Luu TH; Nonzee N; Trifilio S; Sartor O; Benson AB; Carson KR; Edwards BJ; Gilchrist-Scott D; Kuzel TM; Raisch DW; Tallman MS; West DP; Hirschfeld S; Grillo-Lopez AJ; Bennett CL
    J Clin Oncol; 2009 Sep; 27(26):4398-405. PubMed ID: 19636013
    [TBL] [Abstract][Full Text] [Related]  

  • 16. "Dangling" Accelerated Approvals in Oncology.
    Beaver JA; Pazdur R
    N Engl J Med; 2021 May; 384(18):e68. PubMed ID: 33882220
    [No Abstract]   [Full Text] [Related]  

  • 17. Significant FDA approvals in 1999.
    McGinnis TJ
    Am Fam Physician; 2000 Apr; 61(8):2531-3. PubMed ID: 10794586
    [No Abstract]   [Full Text] [Related]  

  • 18. Innovating by developing new uses of already-approved drugs: trends in the marketing approval of supplemental indications.
    DiMasi JA
    Clin Ther; 2013 Jun; 35(6):808-18. PubMed ID: 23726388
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FDA grants accelerated approval for ibrutinib for CLL.
    Dangi-Garimella S
    Am J Manag Care; 2014 Mar; 20(5 Spec No.):E10. PubMed ID: 25618623
    [No Abstract]   [Full Text] [Related]  

  • 20. Comparative study on anticancer drug access times between FDA, EMA and the French temporary authorisation for use program over 13 years.
    Jacquet E; Kerouani-Lafaye G; Grude F; Goncalves S; Lorence A; Turcry F; Brunel L; Belgodere L; Monard A; Guyader G; Boudali L; Albin N
    Eur J Cancer; 2021 May; 149():82-90. PubMed ID: 33838392
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.